Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BIIB144 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BIIB144 Cohort 1 | EXPERIMENTAL | Participants will receive Dose A of BIIB144 or a matching placebo via intravenous (IV) infusion on Day 1. |
| BIIB144 Cohort 2 | EXPERIMENTAL | Participants will receive Dose B of BIIB144 or a matching placebo via IV infusion on Day 1. |
| BIIB144 Cohort 3 | EXPERIMENTAL | Participants will receive Dose C of BIIB144 or a matching placebo via IV infusion on Day 1. |
| BIIB144 Cohort 4 | EXPERIMENTAL | Participants will receive Dose D of BIIB144 or a matching placebo via IV infusion on Day 1. |
| BIIB144 Cohort 5 | EXPERIMENTAL | Participants will receive Dose E of BIIB144 or a matching placebo via IV infusion on Day 1. |
| BIIB144 Cohort 6 | EXPERIMENTAL | Participants will receive Dose F of BIIB144 or a matching placebo via IV infusion on Day 1. |
| Name | Type | Description |
|---|---|---|
| BIIB144 | DRUG | Administered IV |
| Placebo | DRUG | Administered IV |
Key Inclusion Criteria: * Have a body mass index (BMI) between 18 and 32 kilograms per square metre (kg/m\^2), inclusive, at Screening. * Must be in good health as determined by the Investigator, based on medical history and Screening evaluations. Key Exclusion Criteria: * History of any clinical...
BIIB144 is an investigational small molecule drug being developed by Biogen Inc. It is currently in Phase 1 clinical development, with one active trial evaluating it in healthy adult volunteers. No approved indication has been announced for BIIB144.
BIIB144 is being developed by Biogen Inc., which trades on the Nasdaq under the ticker BIIB. Biogen is the sponsor of the Phase 1 study of BIIB144 listed on ClinicalTrials.gov.
BIIB144 is in Phase 1 clinical development. It has one active, recruiting Phase 1 trial and no completed trials. As an investigational drug, it has not been approved by the FDA for any indication.
BIIB144 is being studied in one Phase 1 trial, NCT07662148, titled a study of the safety of a single dose of BIIB144 and how it is processed in the body of healthy adult participants ages 18 to 55 as compared to placebo. The trial is recruiting in the United States and plans to enroll 48 participants.
The Phase 1 trial of BIIB144, NCT07662148, is a randomized, double-blind, controlled study in healthy adult volunteers ages 18 to 55. It evaluates a single dose of BIIB144 compared with placebo, with a planned enrollment of 48 participants. It is recruiting in the United States.